Header Logo

Connection

Anthony Rothschild to Middle Aged

Back to Details
This is a "connection" page, showing publications Anthony Rothschild has written about Middle Aged.
Anthony Rothschild
Connection Strength
0.944
Middle Aged
  1. Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Brown K, Lewis D, Gutin A, Jablonski MR, Greden JF. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021 02; 296:113649.
    View in: PubMed
    Score: 0.055
  2. Marsh WK, Penny JL, Rothschild AJ. Vitamin D supplementation in bipolar depression: A double blind placebo controlled trial. J Psychiatr Res. 2017 12; 95:48-53.
    View in: PubMed
    Score: 0.044
  3. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry. 2014 Jan; 55(1):1-10.
    View in: PubMed
    Score: 0.034
  4. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec; 22(12):858-66.
    View in: PubMed
    Score: 0.031
  5. Marsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll-Desrosiers AR, Rothschild AJ. Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar Disord. 2012 Aug; 14(5):515-26.
    View in: PubMed
    Score: 0.031
  6. Marsh WK, Brown AP, Rothschild AJ. Manic episode after total abdominal hysterectomy with bilateral salpingo-oophorectomy: case report. Menopause. 2012 Apr; 19(4):476-8.
    View in: PubMed
    Score: 0.030
  7. Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
    View in: PubMed
    Score: 0.024
  8. Glezer A, Byatt N, Cook R, Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. J Affect Disord. 2009 Sep; 117(1-2):18-23.
    View in: PubMed
    Score: 0.024
  9. Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, Fratoni S, Gabriele M, Kasapinovic S, Meyers BS. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008 Aug; 69(8):1293-6.
    View in: PubMed
    Score: 0.024
  10. Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
    View in: PubMed
    Score: 0.019
  11. Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.
    View in: PubMed
    Score: 0.018
  12. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004 Aug; 24(4):365-73.
    View in: PubMed
    Score: 0.018
  13. Kim HK, Voineskos AN, Neufeld NH, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Rothschild AJ, Whyte EM, Mulsant BH. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024 Aug; 29(8):2459-2466.
    View in: PubMed
    Score: 0.017
  14. Banerjee S, Wu Y, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Oliver LD, Power JD, Rothschild AJ, Sirey JA, Voineskos AN, Whyte EM, Alexopoulos GS, Flint AJ. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning. Psychol Med. 2024 Apr; 54(6):1142-1151.
    View in: PubMed
    Score: 0.017
  15. Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003 Apr; 64(4):390-6.
    View in: PubMed
    Score: 0.016
  16. Hugunin J, Yuan Y, Baek J, Clark RE, Rothschild AJ, Lapane KL, Ulbricht CM. Characteristics of Working-Age Adults With Schizophrenia Newly Admitted to Nursing Homes. J Am Med Dir Assoc. 2022 07; 23(7):1227-1235.e3.
    View in: PubMed
    Score: 0.015
  17. Hugunin J, Yuan Y, Rothschild AJ, Lapane KL, Ulbricht CM. Risk factors associated with suicidal ideation in newly admitted working-age nursing home residents. J Affect Disord. 2021 12 01; 295:243-249.
    View in: PubMed
    Score: 0.015
  18. Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, Voineskos AN, Marino P, Alexopoulos GS. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol. 2021 Mar-Apr 01; 41(2):196-199.
    View in: PubMed
    Score: 0.014
  19. Flint AJ, Rothschild AJ, Whyte EM, Alexopoulos GS, Mulsant BH, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Meyers BS. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. Am J Geriatr Psychiatry. 2021 07; 29(7):645-654.
    View in: PubMed
    Score: 0.014
  20. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Lerch JP, Flint AJ. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020 07 01; 77(7):674-683.
    View in: PubMed
    Score: 0.013
  21. Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Macaluso M, Hain DT, Aguilar AL, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Res. 2020 08; 290:113017.
    View in: PubMed
    Score: 0.013
  22. Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol. 2000 Feb; 20(1):7-11.
    View in: PubMed
    Score: 0.013
  23. Thase ME, Parikh SV, Rothschild AJ, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Greden JF. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. J Clin Psychiatry. 2019 10 31; 80(6).
    View in: PubMed
    Score: 0.013
  24. Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. 2019 09 05; 381(10):903-911.
    View in: PubMed
    Score: 0.013
  25. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019 08 20; 322(7):622-631.
    View in: PubMed
    Score: 0.013
  26. Bingham KS, Whyte EM, Mulsant BH, Rothschild AJ, Rudorfer MV, Marino P, Banerjee S, Butters MA, Alexopoulos GS, Meyers BS, Flint AJ. Health-related quality of life in remitted psychotic depression?. J Affect Disord. 2019 09 01; 256:373-379.
    View in: PubMed
    Score: 0.012
  27. Moore BE, Rothschild AJ. Treatment of antidepressant-induced sexual dysfunction. Hosp Pract (1995). 1999 Jan 15; 34(1):89-91, 95-6.
    View in: PubMed
    Score: 0.012
  28. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 04; 111:59-67.
    View in: PubMed
    Score: 0.012
  29. Neufeld NH, Mulsant BH, Dickie EW, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Hoptman MJ, Nazeri A, Downar J, Flint AJ, Voineskos AN. Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. EBioMedicine. 2018 Oct; 36:446-453.
    View in: PubMed
    Score: 0.012
  30. Bingham KS, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, Artis AS, Alexopoulos GS, Flint AJ. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018 09; 138(3):267-273.
    View in: PubMed
    Score: 0.012
  31. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998 Jun; 59(6):279-88.
    View in: PubMed
    Score: 0.012
  32. Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, Slavin KV, Berman J, McKhann GM, Patil PG, Rittberg BR, Abosch A, Pandurangi AK, Holloway KL, Lam RW, Honey CR, Neimat JS, Henderson JM, DeBattista C, Rothschild AJ, Pilitsis JG, Espinoza RT, Petrides G, Mogilner AY, Matthews K, Peichel D, Gross RE, Hamani C, Lozano AM, Mayberg HS. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017 11; 4(11):839-849.
    View in: PubMed
    Score: 0.011
  33. Bingham KS, Rothschild AJ, Mulsant BH, Whyte EM, Meyers BS, Banerjee S, Szanto K, Flint AJ. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1149-1154.
    View in: PubMed
    Score: 0.011
  34. Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2017 Jun; 25(6):672-679.
    View in: PubMed
    Score: 0.011
  35. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Hum Psychopharmacol. 2016 05; 31(3):252-5.
    View in: PubMed
    Score: 0.010
  36. Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. Arch Womens Ment Health. 2016 10; 19(5):769-78.
    View in: PubMed
    Score: 0.010
  37. Rothschild AJ. Delirium: an SSRI-benztropine adverse effect? J Clin Psychiatry. 1995 Nov; 56(11):537.
    View in: PubMed
    Score: 0.010
  38. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clin Pharmacokinet. 2015 Nov; 54(11):1161-8.
    View in: PubMed
    Score: 0.010
  39. Ulbricht CM, Rothschild AJ, Lapane KL. Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. J Womens Health (Larchmt). 2016 05; 25(5):464-72.
    View in: PubMed
    Score: 0.010
  40. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995 Oct; 152(10):1514-6.
    View in: PubMed
    Score: 0.010
  41. Ulbricht CM, Rothschild AJ, Lapane KL. The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. J Affect Disord. 2015 Dec 01; 188:270-7.
    View in: PubMed
    Score: 0.010
  42. Bingham KS, Whyte EM, Meyers BS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2015 Dec; 23(12):1270-1275.
    View in: PubMed
    Score: 0.010
  43. Gerretsen P, Flint AJ, Whyte EM, Rothschild AJ, Meyers BS, Mulsant BH. Impaired insight into delusions predicts treatment outcome during a randomized controlled trial for Psychotic Depression (STOP-PD study). J Clin Psychiatry. 2015 Apr; 76(4):427-33.
    View in: PubMed
    Score: 0.009
  44. ?stergaard SD, Pedersen CH, Uggerby P, Munk-J?rgensen P, Rothschild AJ, Larsen JI, G?tzsche C, S?ndergaard MG, Bille AG, Bolwig TG, Larsen JK, Bech P. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord. 2015 Mar 01; 173:261-8.
    View in: PubMed
    Score: 0.009
  45. Bodenlos JS, Schneider KL, Oleski J, Gordon K, Rothschild AJ, Pagoto SL. Vagus nerve stimulation and food intake: effect of body mass index. J Diabetes Sci Technol. 2014 May; 8(3):590-5.
    View in: PubMed
    Score: 0.009
  46. Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Compr Psychiatry. 2014 Jul; 55(5):1069-76.
    View in: PubMed
    Score: 0.009
  47. ?stergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord. 2014 May; 160:68-73.
    View in: PubMed
    Score: 0.009
  48. Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. J Clin Psychiatry. 2014 Jan; 75(1):62-8.
    View in: PubMed
    Score: 0.009
  49. Leadholm AK, Rothschild AJ, Nielsen J, Bech P, Ostergaard SD. Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. J Affect Disord. 2014 Mar; 156:119-25.
    View in: PubMed
    Score: 0.009
  50. Deligiannidis KM, Rothschild AJ, Barton BA, Kroll-Desrosiers AR, Meyers BS, Flint AJ, Whyte EM, Mulsant BH. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. J Clin Psychiatry. 2013 Oct; 74(10):1003-9.
    View in: PubMed
    Score: 0.008
  51. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biol Psychiatry. 1993 Sep 15; 34(6):392-400.
    View in: PubMed
    Score: 0.008
  52. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993 Sep; 54(9):338-42.
    View in: PubMed
    Score: 0.008
  53. ?stergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ. Measuring psychotic depression. Acta Psychiatr Scand. 2014 Mar; 129(3):211-20.
    View in: PubMed
    Score: 0.008
  54. Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013 Jun; 33(3):391-7.
    View in: PubMed
    Score: 0.008
  55. Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial. Am J Geriatr Psychiatry. 2014 Apr; 22(4):332-6.
    View in: PubMed
    Score: 0.008
  56. Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. J Nerv Ment Dis. 2013 Apr; 201(4):266-73.
    View in: PubMed
    Score: 0.008
  57. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Mulsant BH, Rudorfer MV, Marino P. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II. BMC Psychiatry. 2013 Jan 25; 13:38.
    View in: PubMed
    Score: 0.008
  58. Weissman J, Flint A, Meyers B, Ghosh S, Mulsant B, Rothschild A, Whyte E. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Res. 2012 May 30; 197(3):221-6.
    View in: PubMed
    Score: 0.008
  59. Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt AT. Relationships between multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci. 2011; 23(2):198-200.
    View in: PubMed
    Score: 0.007
  60. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.007
  61. Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, Samson JA, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry. 1989 Oct; 26(6):565-75.
    View in: PubMed
    Score: 0.006
  62. Schaffer A, Flint AJ, Smith E, Rothschild AJ, Mulsant BH, Szanto K, Peasley-Miklus C, Heo M, Papademetriou E, Meyers BS. Correlates of suicidality among patients with psychotic depression. Suicide Life Threat Behav. 2008 Aug; 38(4):403-14.
    View in: PubMed
    Score: 0.006
  63. Kamara TS, Whyte EM, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Papademetriou E, Mathis ER, Meyers BS. Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features? J Affect Disord. 2009 Jan; 112(1-3):250-5.
    View in: PubMed
    Score: 0.006
  64. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, Flint AJ, Mulsant BH, Meyers BS. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 2008 May; 23(3):130-7.
    View in: PubMed
    Score: 0.006
  65. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
    View in: PubMed
    Score: 0.006
  66. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.005
  67. Rothschild AJ, Schatzberg AF, Langlais PJ, Lerbinger JE, Miller MM, Cole JO. Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Res. 1987 Feb; 20(2):143-53.
    View in: PubMed
    Score: 0.005
  68. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007 Feb; 68(2):194-200.
    View in: PubMed
    Score: 0.005
  69. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 Feb; 29(2):385-92.
    View in: PubMed
    Score: 0.004
  70. Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. Br J Psychiatry. 1982 Nov; 141:471-4.
    View in: PubMed
    Score: 0.004
  71. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002 Sep 01; 52(5):386-92.
    View in: PubMed
    Score: 0.004
  72. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry. 2000 Jul; 157(7):1095-100.
    View in: PubMed
    Score: 0.003
  73. Schatzberg AF, Samson JA, Rothschild AJ, Bond TC, Regier DA. McLean Hospital depression research facility: early-onset phobic disorders and adult-onset major depression. Br J Psychiatry Suppl. 1998; (34):29-34.
    View in: PubMed
    Score: 0.003
  74. Schatzberg AF, Samson JA, Rothschild AJ, Luciana MM, Bruno RF, Bond TC. Depression secondary to anxiety: findings from the McLean Hospital Depression Research Facility. Psychiatr Clin North Am. 1990 Dec; 13(4):633-49.
    View in: PubMed
    Score: 0.002
  75. Frishman WH, Garofalo JL, Rothschild A, Rothschild M, Greenberg SM, Soberman J. The nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Cardiol. 1989 Sep 19; 64(11):65F-69F.
    View in: PubMed
    Score: 0.002
  76. Frishman WH, Garofalo JL, Rothschild A, Rothschild M, Greenberg SM, Soberman J. Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience. Am J Med. 1987 Dec 21; 83(6B):15-9.
    View in: PubMed
    Score: 0.001
  77. Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, family history, and DST response: a pilot study. Biol Psychiatry. 1986 Nov; 21(13):1239-46.
    View in: PubMed
    Score: 0.001
  78. Schatzberg AF, Rothschild AJ, Gerson B, Lerbinger JE, Schildkraut JJ. Toward a biochemical classification of depressive disorders IX. DST results and platelet MAO activity. Br J Psychiatry. 1985 Jun; 146:633-7.
    View in: PubMed
    Score: 0.001
  79. Rosenbaum AH, Schatzberg AF, MacLaughlin RA, Snyder K, Jiang NS, Ilstrup D, Rothschild AJ, Kliman B. The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. Am J Psychiatry. 1984 Dec; 141(12):1550-5.
    View in: PubMed
    Score: 0.001
  80. Hudson JI, Hudson MS, Rothschild AJ, Vignati L, Schatzberg AF, Melby JC. Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch Gen Psychiatry. 1984 Nov; 41(11):1086-9.
    View in: PubMed
    Score: 0.001
  81. Schatzberg AF, Orsulak PJ, Rothschild AJ, Salomon MS, Lerbinger J, Kizuka PP, Cole JO, Schildkraut JJ. Platelet MAO activity and the dexamethasone suppression test in depressed patients. Am J Psychiatry. 1983 Sep; 140(9):1231-3.
    View in: PubMed
    Score: 0.001
  82. Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, MacLaughlin RA, Sullivan MA, Cole JO. The dexamethasone suppression test: identification of subtypes of depression. Am J Psychiatry. 1983 Jan; 140(1):88-91.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.